Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$130.71
+0.2%
$130.35
$99.71
$141.23
$226.69B0.86.08 million shs8.51 million shs
Boston Scientific Co. stock logo
BSX
Boston Scientific
$102.90
+0.2%
$98.53
$70.97
$107.17
$152.20B0.736.34 million shs6.70 million shs
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$515.80
+0.2%
$506.68
$367.39
$616.00
$184.87B1.551.62 million shs1.65 million shs
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
$0.34
-1.7%
$0.61
$0.30
$29.00
$3.82M1.593.99 million shs1.28 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.80%-0.96%-0.20%+2.10%+21.68%
Boston Scientific Co. stock logo
BSX
Boston Scientific
+0.51%+8.14%+3.42%-0.10%+41.68%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
+0.17%+7.55%+4.69%-10.10%+37.62%
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
-4.81%-12.70%-10.96%-91.05%-96.34%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8882 of 5 stars
2.44.04.24.53.52.52.5
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.4388 of 5 stars
3.53.00.04.22.72.51.3
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
4.6059 of 5 stars
3.44.00.04.02.62.51.9
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
0.4501 of 5 stars
0.02.00.00.03.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.84
Moderate Buy$142.599.09% Upside
Boston Scientific Co. stock logo
BSX
Boston Scientific
3.04
Buy$114.5211.29% Upside
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
2.75
Moderate Buy$598.9516.12% Upside
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest RSLS, ABT, ISRG, and BSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/25/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$118.00 ➝ $125.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$113.00 ➝ $115.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$116.00 ➝ $120.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$113.00 ➝ $117.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$110.00 ➝ $112.00
4/24/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$115.00 ➝ $120.00
4/24/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$684.00 ➝ $635.00
4/23/2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$124.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$630.00 ➝ $605.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$670.00 ➝ $575.00
4/23/2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$605.00 ➝ $590.00
(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.40$5.63 per share23.22$22.36 per share5.85
Boston Scientific Co. stock logo
BSX
Boston Scientific
$17.55B8.67$3.57 per share28.86$14.91 per share6.90
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$8.71B21.21$6.79 per share75.93$46.41 per share11.11
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
$8.01M0.48N/AN/A$29.49 per share0.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.0922.812.5231.95%20.74%11.19%7/17/2025 (Estimated)
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.85B$1.3782.3231.862.7911.07%17.80%9.85%N/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$2.32B$6.8280.4767.605.8527.81%14.55%12.88%7/17/2025 (Estimated)
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
-$11.39M-$13.72N/AN/A-86.36%-179.83%-91.48%5/21/2025 (Estimated)

Latest RSLS, ABT, ISRG, and BSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2025Q1 2025
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
4/22/2025Q1 2025
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
$1.71$1.81+$0.10$1.92$2.19 billion$2.25 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
4/4/2025Q4 2024
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
-$4.06-$1.89+$2.17-$1.89$3.17 million$1.81 million
2/5/2025Q4 2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.65$0.70+$0.05$0.38$4.42 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.81%+7.17%30.61%54 Years
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/AN/AN/AN/AN/A
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
N/AN/AN/AN/AN/A

Latest RSLS, ABT, ISRG, and BSX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.75%4/15/20254/15/20255/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.14
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.41
1.08
1.02
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
N/A
4.07
3.22
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
N/A
1.33
0.60

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
83.64%
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
22.06%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
0.70%
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.73 billion1.73 billionOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
45,0001.48 billion1.47 billionOptionable
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
12,100358.42 million352.97 millionOptionable
ReShape Lifesciences Inc. stock logo
RSLS
ReShape Lifesciences
5011.28 million729,000Not Optionable

Recent News About These Companies

ReShape Lifesciences enters agreement with Haifa
ReShape Lifesciences signs distribution agreement with Liaison Medical
ReShape Lifesciences 2.6M share Secondary priced at $2.33

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$130.71 +0.21 (+0.16%)
As of 03:59 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Boston Scientific stock logo

Boston Scientific NYSE:BSX

$102.90 +0.16 (+0.16%)
As of 03:59 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Intuitive Surgical stock logo

Intuitive Surgical NASDAQ:ISRG

$515.80 +0.91 (+0.18%)
As of 04:00 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

ReShape Lifesciences stock logo

ReShape Lifesciences NASDAQ:RSLS

$0.34 -0.01 (-1.74%)
As of 04:00 PM Eastern

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.